Clinical Trial Update: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing intensive versus relaxed ranibizumab regimens for subfoveal choroidal neovascularization due to wet age-related macular degeneration; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD | Phase 4 | Status: COMPLETED | Results posted: 2019-10-23